Supply Chain

Insight from the top performers on Gartner's Healthcare Supply Chain 25.

The controversy surrounding the cost of EpiPen's did not stop Fortune from including Mylan CEO Heather Bresch on its "Most Powerful Women" list for 2016.

The Food and Drug Administration will conduct a "thorough investigation" of allegations that St. Jude Medical's heart devices have cybersecurity vulnerabilities, according to Reuters.

Hillary Clinton's plan to monitor and lower the cost of prescription drugs will hinder investments into new drugs and negatively impact consumers Pfizer's CEO Ian Read said Thursday during a webcast at the Wells Fargo's healthcare conference in Boston.

While the pharmaceutical industry has found itself under increasing scrutiny for high drug prices , Fortune recently highlighted the good deeds of four drugmakers in its 2016 "Change the World" list.

Medical device makers are feeling the weight of the Food and Drug Administration's unique device identifier regulations.

While Mylan recently announced it would provide a generic version of its controversially expensive EpiPen, Consumer Reports magazine acknowledged that a cheaper version of the medication already exists.

Prescriptions for Mylan's life-saving EpiPen medications have increased over the past four years, peaking every year in August. Last month, the number of prescriptions surpassed totals from the previous three Augusts, according to a report from athenahealth.

While Mylan CEO Heather Bresch has faced immense backlash for the rising cost of EpiPens and her correspondingly high salary, her father, Sen. Joe Manchin (D-W.Va.) is defending his daughter.

A Senate panel will look into Mylan's controversial price markups for the Amsterdam-based drugmakers life-saving EpiPen medication, reported NBC News.